V520

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIV InfectionsHIV-1HIV-1 Infection

Phase 1

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

CompletedNCT00849732

Merck Sharp & Dohme LLCHIV-1, HIV Infections

Start: 2003-06-30End: 2011-02-28Updated: 2015-02-27

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

CompletedNCT00894114

Merck Sharp & Dohme LLCHIV-1 Infection

Start: 2003-05-31End: 2009-06-30Updated: 2015-05-28

Related Papers

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

2011-04-1338 citations